RecruitingPhase 2NCT05385549
5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
Studying Gastrointestinal stromal tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Asan Medical Center
- Intervention
- Imatinib Mesylate(drug)
- Enrollment
- 35 target
- Eligibility
- 20 years · All sexes
- Timeline
- 2022 – 2030
Study locations (1)
- Asan Medical Center, University of Ulsan College of Medicine, Seoul, Seoul, South Korea
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05385549 on ClinicalTrials.govOther trials for Gastrointestinal stromal tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07171203Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal TumorUniversity of California, San Diego
- RECRUITINGNANCT07405125Safety of Robotic Surgery for GISTs at Special Anatomic SitesThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE3NCT07218926A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapyGlaxoSmithKline
- RECRUITINGPHASE1NCT06655246A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)Kura Oncology, Inc.
- RECRUITINGNANCT06926374Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic SurgeryChinese University of Hong Kong
- RECRUITINGNANCT07411118RCT of EFTR Versus STER for GIST TreatmentChinese University of Hong Kong
- RECRUITINGPHASE1, PHASE2NCT06630234A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)Deciphera Pharmaceuticals, LLC
- RECRUITINGPHASE3NCT06640361A Study of Olverembatinib in SDH-deficient GIST.Ascentage Pharma Group Inc.